Protocol Ledger

NCT07503561 · Phase II · RECRUITING

A Trial to Evaluate the Safety, Tolerability and Efficacy of AIC263029 in Kidney Transplant Recipients With BKV Infection

Interventional Phase II clinical trial protocol NCT07503561 sponsored by AiCuris Anti-infective Cures AG in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-10-05 Enrollment: 24 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07503561
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)24 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07503561
Protocol FieldVerified Registry Value
NCT IdentifierNCT07503561
Consolidated Lead SponsorAiCuris Anti-infective Cures AG
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment24 participants (ESTIMATED)
Registered Start Date2026-10-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI